HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
ALS2
alsin Rho guanine nucleotide exchange factor ALS2
Chromosome 2 Β· 2q33.1
NCBI Gene: 57679Ensembl: ENSG00000003393.16HGNC: HGNC:443UniProt: A0A7P0T8F3
78PubMed Papers
23Diseases
0Drugs
119Pathogenic Variants
RESEARCH IMPACT
Variant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
GTPase activator activitycentrosomedendriteguanyl-nucleotide exchange factor activityinfantile-onset ascending hereditary spastic paralysisjuvenile primary lateral sclerosisamyotrophic lateral sclerosis type 2, juvenileamyotrophic lateral sclerosis
✦AI Summary

ALS2 encodes alsin, a 184-kDa multi-domain protein functioning as a guanine nucleotide exchange factor (GEF) for the small GTPase Rab5 1. The protein contains three GEF domains (RCC1-like, DH/PH, and VPS9) and eight MORN motifs, enabling activation of Rab5 and regulation of endosomal trafficking and membrane dynamics 2. ALS2 promotes neurite outgrowth and protects motor neurons against excitotoxicity and oxidative stress through Rac1/phosphatidylinositol-3 kinase/Akt3 signaling pathways 3. Loss-of-function ALS2 mutations cause three related motor neuron diseases: infantile-onset ascending hereditary spastic paralysis (IAHSP), juvenile primary lateral sclerosis (JPLS), and juvenile amyotrophic lateral sclerosis (JALS), characterized by progressive degeneration of upper motor neurons 4. Most disease-causing mutations are premature termination variants resulting in loss of ALS2 function 1. Mechanistically, ALS2 dysfunction impairs endosomal trafficking and lysosomal biogenesis, representing a broader convergence point in ALS pathogenesis alongside other vesicle trafficking genes 5. Clinically, ALS2 mutations represent rare autosomal recessive disorders with insidious onset progressive spastic paraparesis, contractures, and dysarthria 4. Understanding ALS2's role in vesicle trafficking and motor neuron survival has therapeutic implications for broader ALS spectrum disorders.

Sources cited
1
ALS2 encodes a 184-kDa protein with three GEF domains (RCC1-like, DH/PH, VPS9); ALS2 activates Rab5 and regulates endosomal trafficking; mutations cause ALS2, JPLS, and IAHSP
PMID: 15651293
2
ALS2 is a 1657 amino acid protein with three GEF domains and eight MORN motifs; activates Rab5; promotes neurite outgrowth and protects against cytotoxicity
PMID: 17566607
3
Alsin suppresses motoneuronal death through Rac1/phosphatidylinositol-3 kinase/Akt3 pathway
PMID: 16909018
4
ALS2 mutations cause IAHSP, JPLS, and JALS with progressive spastic paraparesis, contractures, and dysarthria; includes nonsense and frameshift variants
PMID: 39424348
5
ALS2 rare mutations converge mechanistically on vesicle trafficking defects in ALS and FTD pathogenesis
PMID: 29400714
Disease Associationsβ“˜23
infantile-onset ascending hereditary spastic paralysisOpen Targets
0.77Strong
juvenile primary lateral sclerosisOpen Targets
0.75Strong
amyotrophic lateral sclerosis type 2, juvenileOpen Targets
0.74Strong
amyotrophic lateral sclerosisOpen Targets
0.58Moderate
familial amyotrophic lateral sclerosisOpen Targets
0.57Moderate
genetic disorderOpen Targets
0.47Moderate
juvenile amyotrophic lateral sclerosisOpen Targets
0.46Moderate
ALS2-related motor neuron diseaseOpen Targets
0.45Moderate
Tip-toe gaitOpen Targets
0.34Weak
Abnormal central motor functionOpen Targets
0.33Weak
parasitic infectionOpen Targets
0.32Weak
SpasticityOpen Targets
0.26Weak
Abnormal cerebral white matter morphologyOpen Targets
0.26Weak
Global developmental delayOpen Targets
0.26Weak
HypertyrosinemiaOpen Targets
0.26Weak
HypokinesiaOpen Targets
0.26Weak
Limb dystoniaOpen Targets
0.26Weak
chronic obstructive pulmonary diseaseOpen Targets
0.22Weak
cardiac arrhythmiaOpen Targets
0.21Weak
cervical carcinomaOpen Targets
0.21Weak
Amyotrophic lateral sclerosis 2UniProt
Infantile-onset ascending spastic paralysisUniProt
Juvenile primary lateral sclerosisUniProt
Pathogenic Variants119
NM_020919.4(ALS2):c.2737C>T (p.Arg913Ter)Pathogenic
not provided|Infantile-onset ascending hereditary spastic paralysis
β˜…β˜…β˜†β˜†2026β†’ Residue 913
NM_020919.4(ALS2):c.3520A>T (p.Lys1174Ter)Pathogenic
Infantile-onset ascending hereditary spastic paralysis|Amyotrophic lateral sclerosis type 2, juvenile|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 1174
NM_020919.4(ALS2):c.3158G>A (p.Trp1053Ter)Pathogenic
not provided|Amyotrophic lateral sclerosis type 2, juvenile;Infantile-onset ascending hereditary spastic paralysis;Juvenile primary lateral sclerosis|Tip-toe gait|Infantile-onset ascending hereditary spastic paralysis
β˜…β˜…β˜†β˜†2025β†’ Residue 1053
NM_020919.4(ALS2):c.601C>T (p.Arg201Ter)Pathogenic
Juvenile primary lateral sclerosis;Infantile-onset ascending hereditary spastic paralysis;Amyotrophic lateral sclerosis type 2, juvenile|Infantile-onset ascending hereditary spastic paralysis|Amyotrophic lateral sclerosis type 2, juvenile
β˜…β˜…β˜†β˜†2025β†’ Residue 201
NM_020919.4(ALS2):c.2761C>T (p.Arg921Ter)Pathogenic
Infantile-onset ascending hereditary spastic paralysis|not provided|Amyotrophic lateral sclerosis type 2, juvenile
β˜…β˜…β˜†β˜†2024β†’ Residue 921
NM_020919.4(ALS2):c.1649C>T (p.Pro550Leu)Likely pathogenic
Amyotrophic lateral sclerosis type 2, juvenile
β˜…β˜…β˜†β˜†2024β†’ Residue 550
NM_020919.4(ALS2):c.880_881del (p.Leu294fs)Pathogenic
not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 294
NM_020919.4(ALS2):c.470G>A (p.Cys157Tyr)Likely pathogenic
Infantile-onset ascending hereditary spastic paralysis|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 157
NM_020919.4(ALS2):c.3047dup (p.Tyr1017fs)Likely pathogenic
not provided|ALS2-related motor neuron disease
β˜…β˜…β˜†β˜†2023β†’ Residue 1017
NM_020919.4(ALS2):c.3415C>T (p.Arg1139Ter)Pathogenic
not provided|Inborn genetic diseases|Amyotrophic lateral sclerosis type 2, juvenile|Infantile-onset ascending hereditary spastic paralysis|Amyotrophic lateral sclerosis type 2, juvenile;Juvenile primary lateral sclerosis;Infantile-onset ascending hereditary spastic paralysis
β˜…β˜…β˜†β˜†2023β†’ Residue 1139
NM_020919.4(ALS2):c.2580+2T>CPathogenic
Infantile-onset ascending hereditary spastic paralysis|Amyotrophic lateral sclerosis type 2, juvenile
β˜…β˜…β˜†β˜†2023
NM_020919.4(ALS2):c.1233T>G (p.Tyr411Ter)Pathogenic
Infantile-onset ascending hereditary spastic paralysis|Infantile-onset ascending hereditary spastic paralysis;Amyotrophic lateral sclerosis type 2, juvenile;Juvenile primary lateral sclerosis
β˜…β˜…β˜†β˜†2023β†’ Residue 411
NM_020919.4(ALS2):c.4381C>T (p.Arg1461Ter)Pathogenic
Amyotrophic lateral sclerosis type 2, juvenile|Infantile-onset ascending hereditary spastic paralysis
β˜…β˜…β˜†β˜†2023β†’ Residue 1461
NM_020919.4(ALS2):c.4626+1G>APathogenic
not provided|Amyotrophic lateral sclerosis type 2, juvenile
β˜…β˜…β˜†β˜†2023
NM_020919.4(ALS2):c.3703-2A>GPathogenic
Infantile-onset ascending hereditary spastic paralysis
β˜…β˜…β˜†β˜†2022
NM_020919.4(ALS2):c.1640+1G>APathogenic
Abnormal central motor function|not provided|Infantile-onset ascending hereditary spastic paralysis
β˜…β˜…β˜†β˜†2022
NM_020919.4(ALS2):c.4573dup (p.Val1525fs)Pathogenic
Amyotrophic lateral sclerosis type 2, juvenile|Infantile-onset ascending hereditary spastic paralysis
β˜…β˜…β˜†β˜†2022β†’ Residue 1525
NM_020919.4(ALS2):c.4270C>T (p.Gln1424Ter)Pathogenic
Juvenile amyotrophic lateral sclerosis|Infantile-onset ascending hereditary spastic paralysis
β˜…β˜…β˜†β˜†2022β†’ Residue 1424
NM_020919.4(ALS2):c.735_738del (p.Glu246fs)Pathogenic
not provided|Infantile-onset ascending hereditary spastic paralysis
β˜…β˜…β˜†β˜†2022β†’ Residue 246
NM_020919.4(ALS2):c.4261C>T (p.Arg1421Ter)Likely pathogenic
Infantile-onset ascending hereditary spastic paralysis|Juvenile primary lateral sclerosis;Infantile-onset ascending hereditary spastic paralysis;Amyotrophic lateral sclerosis type 2, juvenile
β˜…β˜…β˜†β˜†2021β†’ Residue 1421
View on ClinVar β†—
Related Genes
NEK1Protein interaction94%ATXN2Protein interaction91%VAPBProtein interaction91%FIG4Protein interaction91%OPTNProtein interaction91%SETXProtein interaction91%
Tissue Expression6 tissues
Heart
100%
Liver
61%
Brain
44%
Bone Marrow
34%
Lung
32%
Ovary
30%
Gene Interaction Network
Click a node to explore
ALS2NEK1ATXN2VAPBFIG4OPTNSETX
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted Β· UniProt Q96Q42
View on AlphaFold β†—
Constraintβ“˜
LOEUFβ“˜
0.65LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.56 [0.48–0.65]
RankingsWhere ALS2 stands among ~20K protein-coding genes
  • #6,048of 20,598
    Most Researched78
  • #653of 5,498
    Most Pathogenic Variants119 Β· top quartile
  • #4,698of 17,882
    Most Constrained (LOEUF)0.65
Genes detectedALS2
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons.
PMID: 29400714
Nat Med Β· 2018
1.00
2
Phenotype and Genotype of Children with ALS2 gene-Related Disorder.
PMID: 39424348
Neuropediatrics Β· 2025
0.90
3
Nuclear accumulation of CHMP7 initiates nuclear pore complex injury and subsequent TDP-43 dysfunction in sporadic and familial ALS.
PMID: 34321318
Sci Transl Med Β· 2021
0.80
4
ALS2-Related Motor Neuron Diseases: From Symptoms to Molecules.
PMID: 35053075
Biology (Basel) Β· 2022
0.70
5
Molecular and cellular function of ALS2/alsin: implication of membrane dynamics in neuronal development and degeneration.
PMID: 17566607
Neurochem Int Β· 2007
0.60